Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...

Inhibikase Therapeutics (IKT) announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025.Stay Ahead of ...

Inhibikase Therapeutics' chief financial officer, Garth Lees-Rolfe, has resigned from the clinical-stage pharmaceutical company, which has hired David McIntyre as its new finance chief.

(RTTNews) - Inhibikase Therapeutics, Inc. (IKT), a pharmaceutical company, on Monday announced that it has appointed David McIntyre as Chief Financial Officer, effective from April 14. Shares of ...

Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 14.13%, which has investors questioning if this is right time ...

Every investor in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) should be aware of the most powerful shareholder groups. We can see that hedge funds own the lion's share in the company with 31% ownership ...

BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company ...

INHIBIKASE THERAPEUTICS ($IKT) is expected to release its quarterly earnings data on Tuesday, March 25th after market close, per Finnhub. Analysts are expecting ...

BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical ...

New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. ...